Assuntos
Hepacivirus/fisiologia , Hepatite C/virologia , Ferimentos Penetrantes Produzidos por Agulha , Evolução Biológica , Feminino , Hepatite C/imunologia , Hepatite C/transmissão , Anticorpos Anti-Hepatite C/análise , Humanos , Transmissão de Doença Infecciosa do Paciente para o Profissional , Pessoa de Meia-IdadeRESUMO
Intradermal vaccination has been proposed as an alternative for the administration of anti-hepatitis B vaccine. Patients (n=66) with chronic viral hepatitis C without cirrhosis were randomised into two groups (intramuscular, n=38; and intradermal, n=28) for prospective immunisation with 20 microg recombinant vaccine, using an ultra-rapid schedule (doses at 0, 15 and 30 days). Sero-conversion (antibody level >/=10 mU/ml) in the intramuscular group was reached by 20, 40 and 72% of patients at days 15, 30 and 60 compared to 4, 8 and 36% for the intradermal group (P=0.010 at day 60). Additionally, levels rose more rapidly in the intramuscular group (P=0.004). Our results do not support the use of intradermal route of immunisation against HBV in HCV patients.